Literature DB >> 10477713

Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.

T J Hamblin1, Z Davis, A Gardiner, D G Oscier, F K Stevenson.   

Abstract

Despite having several characteristics of naïve B cells, chronic lymphocytic leukemia (CLL) cells have been shown in some cases to have somatically mutated Ig variable region genes, indicating that the cell of origin has passed through the germinal center. A previous study of patients with CLL found an association between lack of somatic mutation and trisomy 12 and, therefore, possibly with a less favorable prognosis. We have sequenced the Ig V(H) genes of the tumor cells of 84 patients with CLL and correlated our findings with clinical features. A total of 38 cases (45.2%) showed >/= 98% sequence homology with the nearest germline V(H) gene; 46 cases (54.8%) showed >2% somatic mutation. Unmutated V(H) genes were significantly associated with V1-69 and D3-3 usage, with atypical morphology; isolated trisomy 12, advanced stage and progressive disease. Survival was significantly worse for patients with unmutated V(H) genes irrespective of stage. Median survival for stage A patients with unmutated V(H) genes was 95 months compared with 293 months for patients whose tumors had mutated V(H) genes (P =.0008). The simplest explanation is that CLL comprises 2 different diseases with different clinical courses. One, arising from a memory B cell, has a benign course, the other, arising from a naïve B cell, is more malignant.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10477713

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  656 in total

Review 1.  New additions to antibody panels in the characterisation of chronic lymphoproliferative disorders.

Authors:  E Matutes
Journal:  J Clin Pathol       Date:  2002-03       Impact factor: 3.411

2.  Enhanced outgrowth of EBV-transformed chronic lymphocytic leukemia B cells mediated by coculture with macrophage feeder cells.

Authors:  Kwan-Ki Hwang; Xi Chen; Daniel M Kozink; Marietta Gustilo; Dawn J Marshall; John F Whitesides; Hua-Xin Liao; Rosa Catera; Charles C Chu; Xiao-Jie Yan; Micah A Luftig; Barton F Haynes; Nicholas Chiorazzi
Journal:  Blood       Date:  2011-12-12       Impact factor: 22.113

3.  Histological and immunoglobulin VH gene analysis of interfollicular small lymphocytic lymphoma provides evidence for two types.

Authors:  D W Bahler; N S Aguilera; C C Chen; S L Abbondanzo; S H Swerdlow
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

4.  Telomere length and telomerase levels delineate subgroups of B-cell chronic lymphocytic leukemia with different biological characteristics and clinical outcomes.

Authors:  Enrica Rampazzo; Laura Bonaldi; Livio Trentin; Carlo Visco; Sonia Keppel; Silvia Giunco; Federica Frezzato; Monica Facco; Elisabetta Novella; Ilaria Giaretta; Paola Del Bianco; Gianpietro Semenzato; Anita De Rossi
Journal:  Haematologica       Date:  2011-09-20       Impact factor: 9.941

Review 5.  Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia.

Authors:  Kumudha Balakrishnan; Varsha Gandhi
Journal:  Expert Opin Investig Drugs       Date:  2012-03-09       Impact factor: 6.206

6.  Mutation analysis of IgVH gene in B-cell chronic lymphocytic leukemia.

Authors:  Feng Wang; Huifen Zhu; Lijuan Zhu; Botao Yin; Guanxin Shen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2002

7.  Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance).

Authors:  John C Byrd; Amy S Ruppert; Nyla A Heerema; Alese E Halvorson; Eva Hoke; Mitchell R Smith; John E Godwin; Stephen Couban; Todd A Fehniger; Michael J Thirman; Martin S Tallman; Frederick R Appelbaum; Richard M Stone; Sue Robinson; Julie E Chang; Sumithra J Mandrekar; Richard A Larson
Journal:  Blood Adv       Date:  2018-07-24

8.  Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact.

Authors:  Panagiotis Baliakas; Sabine Jeromin; Michalis Iskas; Anna Puiggros; Karla Plevova; Florence Nguyen-Khac; Zadie Davis; Gian Matteo Rigolin; Andrea Visentin; Aliki Xochelli; Julio Delgado; Fanny Baran-Marszak; Evangelia Stalika; Pau Abrisqueta; Kristina Durechova; George Papaioannou; Virginie Eclache; Maria Dimou; Theodoros Iliakis; Rosa Collado; Michael Doubek; M Jose Calasanz; Neus Ruiz-Xiville; Carolina Moreno; Marie Jarosova; Alexander C Leeksma; Panayiotis Panayiotidis; Helena Podgornik; Florence Cymbalista; Achilles Anagnostopoulos; Livio Trentin; Niki Stavroyianni; Fred Davi; Paolo Ghia; Arnon P Kater; Antonio Cuneo; Sarka Pospisilova; Blanca Espinet; Anastasia Athanasiadou; David Oscier; Claudia Haferlach; Kostas Stamatopoulos
Journal:  Blood       Date:  2019-01-02       Impact factor: 22.113

9.  Multicolor-FICTION: expanding the possibilities of combined morphologic, immunophenotypic, and genetic single cell analyses.

Authors:  José Ignacio Martín-Subero; Ilse Chudoba; Lana Harder; Stefan Gesk; Werner Grote; Francisco Javier Novo; María José Calasanz; Reiner Siebert
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

10.  Recurrent reciprocal RNA chimera involving YPEL5 and PPP1CB in chronic lymphocytic leukemia.

Authors:  Thirunavukkarasu Velusamy; Nallasivam Palanisamy; Shanker Kalyana-Sundaram; Anagh Anant Sahasrabuddhe; Christopher A Maher; Daniel R Robinson; David W Bahler; Timothy T Cornell; Thomas E Wilson; Megan S Lim; Arul M Chinnaiyan; Kojo S J Elenitoba-Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.